The landscape of metastatic prostate cancer (mPCa) treatment has evolved significantly with the advent of targeted therapies, particularly poly (ADP-ribose) polymerase inhibitors (PARPis). 1 However, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback